BACKGROUND: Rapid point-of-care capillary hepatitis C virus (HCV) RNA quantification could remove barriers to chronic hepatitis C diagnosis and treatment. AIMS: To evaluate the diagnostic accuracy of rapid pointof-care HCV RNA quantification by Cepheid ® 's GeneXpert ® in 100 µl capillary whole blood using our laboratorybased standard quantitative HCV polymerase chain-reaction (PCR) test (Roche Cobas ® Ampliprep/Taqman) with 650 µl venous EDTA plasma as the reference test. in the Infectious Diseases Outpatient Clinic of a Swiss tertiary care hospital, all adults with an indication for HCV RNA quantification (including HCV treatment monitoring) and written informed consent provided venous and capillary blood for parallel testing. Up to October 2018, we used the Xpert ® HCV Viral Load (VL) test (105 min; developed for 1 ml plasma or serum), for which 1 ml Cepheid® buffer was added to 100 µl fingerstick capillary whole blood (~55% plasma). Thereafter, the Xpert ® HCV Viral Load Finger-Stick (VL FS) test (60 min; specifically developed for 100 µl capillary whole blood) was evaluated. RESULTS: (1) Xpert ® HCV VL test. Among 194 paired samples from 88 patients, 99 (51.0%) were positive using Cobas ® in venous plasma. Sensitivity and specificity of the Xpert ® HCV VL test with 100µl capillary whole blood was 97.0% (96/99; 95% confidence interval [CI] 91.5-99.0%) and 94.7% (90/95; 95% CI 88.3-97.7%), respectively. The eight (4.1%) discordant results (three false negative, five false positive) were all under direct acting antiviral (DAA) treatment (week 1-4 or end of treatment), when HCV RNA was near the limit of quantification (highest HCV RNA value missed by Xpert ® 68 IU/ml). Quantifiable results (n = 68) correlated well (R 2 = 0.9165) irrespective of genotype, sex and HIV status. On average, Xpert ® HCV VL test results were 1.32 (±0.34) log IU/ml lower, which corre-sponds to the~18-fold smaller plasma volume used (~55 vs 1000µl). (2) Xpert ® HCV VL FS test: Among 33 paired samples from 23 patients, 15 (45.5%) were positive using Cobas ® in venous plasma. Sensitivity and specificity of the Xpert ® HCV VL FS test with 100 µl capillary whole blood was 100% (15/15; 95% CI 79.6-100%) and 88.9% (16/18; 95% CI 67.2-96.9%), respectively. The two (6.1%) discordant results (both false positive) were under DAA treatment (week 3 and 4), when HCV RNA was near the limit of quantification. Quantifiable results (n = 14) correlated well (R 2 = 0.9899). On average, Xpert ® HCV VL FS test results were 0.10 (±0.17) log IU/ml lower.
Introduction
In order to reach the World Health Organization (WHO) goal "Hepatitis C elimination by 2030", 80% treatment uptake is required [1] . With the latest well-tolerated pangenotypic direct acting antivirals (DAAs) (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) [2, 3] , treatment duration decreased to 8-12 weeks, treatment success increased to 95-100% and genotyping became dispensable [4] . As a consequence, hepatitis C virus (HCV) treatment uptake in the Swiss Association for the Medical Management in Substance Users (SAMMSU) cohort increased from 55 to 65% between 1 May 2017 and 1 May 2018 [5] . However, only those diagnosed by HCV antibody screening, further evaluated with HCV RNA polymerase chain-reaction (PCR) testing and linked to care will eventually receive treatment. Diagnostic gaps in the HCV cascade have been described all over the world [6] [7] [8] [9] , particularly for the high-prevalence population of people who inject drugs with often difficult venous access.
Capillary tests are well accepted and potentially increase screening uptake [10] . Also, point-of-care tests (POCTs) providing results within minutes have been shown to improve linkage to care [11, 12] . However, they can only be recommended if sufficiently reliable. Although reliable rapid HCV antibody tests using capillary whole blood or saliva are already available [13] , there is still need for optimising viraemia detection [14] . Dried blood spots (DB-Ss) were successfully used for HCV genotyping and HCV RNA quantification [15] . However, at 150-250 IU/ml, the detection threshold was significantly higher than in plasma [16] and turn-around times do not allow immediate decision making.
The Xpert ® HCV Viral Load (VL) test is a POCT approved for 1 ml venous plasma or serum (limit of detection [LOD] 4.0 IU/ml, 95% confidence interval [CI] 2.8-5.2) and 6.1 IU/ml, 95% CI 4.2-7.9, respectively). It provides quantitative results within 105 min [17] [18] [19] . So far, only one study in 150 participants evaluated the performance of this test for finger-stick capillary whole blood. Compared with the Abbott ® RealTime HCV Viral Load assay with 500 µl venous plasma, sensitivity was 95.5% (95% CI 84.5-99.4%) and specificity 98.1% (95% CI 93.4-99.8%) [20] . In September 2018, the Xpert ® HCV Viral Load Finger-Stick (VL FS) test, specifically developed for 100 µl capillary whole-blood (LOD 40 IU/ml; 60 min), was approved. Compared with the Abbott ® RealTime HCV Viral Load assay with 500 µl venous plasma, sensitivity was 98.3% (95% CI 91.1-100%) and specificity 100% (95% CI 96.6-100%) (167 participants) [21] . Both studies, conducted by The Kirby Institute in Australia, excluded patients under DAA treatment [20, 21] .
The aim of our prospective study was to evaluate the diagnostic accuracy of rapid point-of-care HCV RNA quantification by GeneXpert ® in 100 µl capillary whole blood overall and in different settings (according to HCV genotype, sex and human immunodeficiency virus [HIV] serostatus, with and without correction for haematocrit, on and off HCV treatment) using our laboratory-based standard quantitative HCV polymerase chain reaction (PCR) test (Roche Cobas ® Ampliprep/Taqman) with 650 µl venous EDTA plasma as the reference test. Until October 2018, we used the Xpert ® HCV VL test (105 min; developed for 1 ml plasma or serum). Thereafter, the Xpert ® HCV VL FS test (60 min; specifically developed for 100 µl capillary whole blood) was evaluated.
Materials and methods

Ethical considerations
The study was approved by the cantonal ethics committee (AG/SO 2012/091; PB_2016-02058). All participants gave written informed consent.
Study design and participants/samples
In a prospective study conducted between November 2016 and May 2019 in the Infectious Diseases Outpatient Clinic of the Cantonal Hospital Aarau, a tertiary care hospital, all adults with an indication for HCV RNA quantification and written informed consent provided both venous and capillary blood for parallel testing. To evaluate suitability of the capillary HCV RNA test for HCV treatment monitoring, specimens were collected during treatment, at the end of treatment (EOT) and 12 weeks thereafter (sustained virological response [SVR]).
The Xpert ® HCV VL test was evaluated between November 2016 and October 2018 (194 paired samples from 88 patients) and the Xpert ® HCV VL FS test between November 2018 and May 2019 (32 paired samples from 23 patients).
Index tests
Xpert ® HCV VL test: 100 µl capillary whole blood collected after a finger stick (MiniCollect Safety Lancet; Greiner Bio-One, Frickenhausen, Germany) into an EDTA minivette (Minivette ® POCT 100 µl EDTA; Sarstedt, Nümbrecht, Germany) were immediately transferred into an Xpert ® HCV VL cartridge (GXHCV-VL-CE-10; Cepheid, Sunnyvale, CA, USA), approved for 1 ml plasma (limit of quantification [LOQ] 10 IU/ml, LOD 4.0 IU/ml, 95% CI 2.8-5.2) or serum; results are available within 105 min. As described by Grebely et al. [20] , 1 ml Cepheid buffer (Cepheid, Sunnyvale, CA, USA) was added with the 1 ml transfer pipette included in the kit. Based on the assumption of an average haematocrit of 45%, 100 µl whole blood contains~55µl plasma, which is~18-fold less than the 1 ml for which the cartridge is approved. Thus, capillary measurements were expected to be 1.3 log IU/ml lower than measurements in 1 ml plasma. Xpert ® HCV VL testing of capillary whole blood was done on a GeneXpert ® with four modules (GXIV-4-L System; Cepheid Sunnyvale, CA, USA).
Xpert ® HCV VL FS test: 100 µl capillary whole-blood collected after a finger stick (see above) were immediately transferred into an Xpert ® HCV VL FS cartridge (GX-HCV-FS-CE-10; Cepheid, Sunnyvale, CA, USA) (approved for 100 µl capillary whole blood (LOQ 100 IU/ml, LOD 40 IU/ml; result within 60 min) and measured with a GeneXpert ® .
Both index tests were used as POCT. The GeneXpert ® containing four modules is connected to a laptop and transportable in a passenger car. For the duration of the study, the GeneXpert ® was situated in the room of the Infectious Diseases Outpatient Clinic where blood sampling is performed. After instruction by the study team, the clinical nurses ran the Xpert ® tests independently. Prior to the capillary blood draw, the GeneXpert ® instrument and the software were started, patient data entered and the Xpert ® cartridge scanned. Immediately after the capillary blood draw, the sample was transferred into the cartridge, which was directly loaded to the prepared GeneXpert ® . Thus, the "puncture-to-test-start time" was less than 1 minute. Since the four modules operate independently of each other, the next test can be loaded while the first is still running. After the Xpert ® test had been started, venepuncture was performed to collect venous plasma for the reference test and the third assay (see below). In the event of an error message from the GeneXpert ® ("insufficient volume errors" occur after 3.5 minutes.), the patient was still available for another capillary blood draw. With the Xpert ® HCV VL test running with 100 µl capillary whole blood and 1 ml buffer solution, we did not observe "insufficient volume errors", whereas complete filling of the 100 µl EDTA minivette is crucial for the Xpert ® HCV VL FS test, which uses only 100 µl capillary whole blood. Therefore, a lancet providing sufficient blood flow should be used. In the case of slow blood flow or air bubbles in the capillary, the blood draw should be repeated in order not to waste a cartridge.
Reference test
HCV RNA in 650 µl venous EDTA plasma was quantified with real-time PCR using the Cobas ® AmpliPrep / Cobas ® TaqMan ® HCV Test CAP/CTM version 2.0 (Roche ® , Ref.
Nr. 05532264) (LOQ 15 IU/ml), which is routinely run once a week in our laboratory. Samples are centrifuged within 6 hours of collection and plasma stored at −20°C until testing. Specimen preparation is automated using the Cobas ® AmpliPrep instrument with amplification and detection automated using the Cobas ® TaqMan ® 48 analyser. The Cobas ® AmpliPrep / Cobas ® TaqMan ® HCV test is based on three major processes: (1) specimen preparation to isolate HCV RNA; (2) reverse transcription of the target RNA to generate complementary DNA (cDNA), and (3) simultaneous PCR amplification of target cDNA and detection with a cleaved dual-labelled oligonucleotide detection probe specific to the target. Primers define a sequence within the highly conserved region of the 5'-untranslated region of the HCV genome. The nucleotide sequence of the primers has been optimized to yield comparable amplification of all HCV genotypes.
Third assay for discordant/discrepant results
In the case of discordance between the index and the reference test, as well as discrepant quantifiable results (>2.3 log IU/ml or <0.3 log IU/ml difference between the Xpert ® HCV VL test with 100 µl capillary whole-blood and the Cobas ® assay with 650 µl venous plasma), an additional 1 ml venous plasma from the same blood draw was tested with the Xpert ® HCV VL test according to the manufacturers' recommendations to differentiate between material-(capillary whole blood vs venous plasma) and test-(Xpert ® vs Cobas ® ) specific causes.
HCV genotyping
HCV genotypes were analysed by means of the VER-SANT ® HCV Genotype 2.0 Assay (LiPA) (Siemens, Zurich, Switzerland), which detects 6 genotypes and 19 subtypes.
Statistical analysis
Data regarding the Xpert ® HCV VL and the Xpert ® HCV VL FS test were analysed separately.
The following measures of accuracy were assessed: sensitivity (proportion of HCV RNA positives correctly identified by the capillary test), specificity (proportion of HCV RNA negatives correctly identified by the capillary test), positive predictive value (PPV; proportion of individuals with a positive capillary test result actually being HCV RNA positive), negative predictive value (NPV; proportion of individuals with a negative capillary test result actually being HCV RNA negative) and the proportion with concordant qualitative results. For the sensitivity/specificity analysis, we only considered qualitative results (detectable or not). "Detectable below 10 IU/ml" (Xpert ® HCV VL test), "detectable below 100 IU/ml" (Xpert ® HCV VL FS test) and "detectable below 15 IU/ml" (Cobas ® assay) counted as positive results. We also determined diagnostic accuracy according to the following indications: pretreatment baseline, on-treatment follow-up, EOT, SVR, screening for reinfection, differentiation between spontaneous clearance and chronic hepatitis C, screening for acute infection.
Paired samples with quantifiable results in both tests underwent correlation analysis. A squared correlation coefficient (R 2 ) and a fitted regression line were calculated.
Primers used by the Xpert ® and the Cobas ® platform might not recognise HCV RNA from different HCV genotypes equally well. Women have a lower haematocrit than men. Thus, on average, the plasma volume contained in 100 µl capillary whole blood is higher in women than in men. In human immunodeficiency virus (HIV) / HCV co-infected patients, there is interaction between the two viruses, resulting in enhanced HCV RNA replication and more rapid progression of HCV-related liver disease in co-infected patients [22, 23] . Accordingly, we investigated the correlation between Xpert ® HCV VL and Cobas ® results stratified by HCV genotype, sex and HIV serostatus and corrected [+log 10 (1000/(100−haematocrit(%))] versus uncorrected for the same-day haematocrit.
For paired quantifiable results, Bland-Altman plots were produced. We plotted the difference between the Cobas ® and the respective Xpert ® results against their average. Correction for the haematocrit was done only for the Xpert ® HCV VL test.
Statistical analyses were performed with Stata Version 12.0 and OpenEpi (www.openepi.com).
Results
Xpert ® HCV VL test
Patient/sample characteristics
Between November 2016 and October 2018, 194 Xpert ® HCV VL tests were performed in 88 patients. Patient and sample characteristics are described in table 1. About 70% of the patients were male, 80% had ever used intravenous drugs, about half were on opioid agonist therapy, all but three were HCV antibody positive and 39% HIV/HCV coinfected. The median age was 48 years. More than half of the patients had more than one test (up to six tests per patient). HCV genotype 1 was the most frequent, followed by genotypes 3 and 4. On average, the same-day haematocrit was 3.3% higher in men than in women.
Qualitative performance and diagnostic accuracy
With the Cobas ® assay in venous plasma (reference test), 51.0% (95% confidence interval [CI] 44.1-58.0%) samples were HCV RNA positive. Compared with this reference test, sensitivity of the Xpert ® HCV VL assay using capillary blood was 97.0% (95% CI 91.5-99.0%) and specificity 94.7% (95% CI 88.3-97.7%) (positive predictive value 95.0%, 95% CI 88.9-97.9%; negative predictive value 96.8%, 95% CI 90.9-98.9%). The proportion with concordant qualitative results was 95.9% (95% CI 92.1-97.9%) (tables 2 and 3).
Among the eight discordant results (three false negative, five false positive), seven were 1 to 4 weeks after initiation of DAA treatment and one at EOT (table 4 ). The highest HCV RNA value missed by the capillary test was 68 IU/ ml. For the other two false negative results, the Cobas ® -result was "<15 IU/ml, detectable below the LOQ". The three positive Cobas ® results were confirmed by additional Xpert ® HCV VL testing of 1 ml venous plasma. For all five false positive results, the capillary Xpert ® HCV VL result was "HCV detected <10 IU/ml". Additional Xpert ® HCV VL testing of 1 ml venous plasma confirmed the capillary measurements and not the negative Cobas ® results.
Quantitative performance
After two pairs of tests were excluded because of problems with capillary blood draw and the reference test, respectively ( status and sex (~5% higher haematocrit in men results iñ 5µl less plasma in 100µl whole blood.) ( fig. 1 ). The equation for the fitted regression line was:
Cobas ® (log IU/ml) = 1.0646 × Xpert ® (log IU/ml) + 1.0428
On average, capillary Xpert ® HCV VL results were 1.32 (±0.34) log IU/ml lower (range 0.44-1.96) (Bland-Altman plot, supplementary fig. S1 in appendix 1). This corresponds to the~18-fold smaller plasma volume used when using 100 µl whole blood with a haematocrit of 45% (55µl plasma) instead of 1 ml plasma (55/1000 = 0.055 = 1/18; log 10 (18) = 1.26).
For 57 (83.8%) of the 68 samples with paired quantifiable results, same-day haematocrit was available (range 31.5-50%; mean 41.8 ± 4.1%; mean in 23 women 39.1 ± 4.0%; mean in 34 men 43.6 ± 3.1%). Correction for the individual haematocrit (+log 10 (1000/(100−haematocrit(%)); range +log 10 (14.6) = 1.16 to +log 10 (20) = 1.30), reduced the mean difference between Cobas ® -and capillary Xpert ® HCV VL results from 1.34 ± 0.33 (range +0.44 to +1.96) to 0.11 ± 0.33 (range −0.83 to +0.77) (Bland-Altman plot, fig. S2 ), but did not improve correlation (R 2 = 0.8906 vs R 2 = 0.8895).
Detectable below the LOQ
Eight Cobas ® -results were "detectable below the LOQ" (15 IU/ml, 1.2 log IU/ml). Two of them were undetectable with the capillary Xpert ® HCV VL test (table 4) and six "detectable below the LOQ" (10 IU/ml, 1.0 log IU/ml). In contrast, 31 capillary Xpert ® HCV VL tests were "detectable below the LOQ" (fig. 2) . The median correspond- ing Cobas ® result was 23 IU/ml (interquartile range [IQR] 7.5-44) and 1.36 log IU/ml (IQR 0.88-1.64), respectively. The two discordant results (both false positive) were under DAA treatment (week 3, genotype 4 and week 4, genotype Figure 3 : Xpert ® HCV Viral Load (VL) test: HCV RNA course for 10 patients with parallel values prior to, during and after HCV-treatment.Cobas = Cobas ® assay with 650 µl venous plasma (limit of quantification 15 IU/ml = 1.2 log IU/ml); Xpert = Xpert ® HCV Viral Load test with 100 µl finger-stick capillary whole blood (~55 µl plasma); prior = prior to HCV treatment; week 1, week 2, week 4, week 6 = respective weeks under HCV treatment; EOT (8) = end of treatment (week 8); EOT (12) = end of treatment (week 12); SVR = sustained virological response; 0 = HCV RNA not detectable.For unquantifiable positive Cobas ® results ("detectable below the limit of quantification of 15 IU/ml [1.2 log IU/ml]"), the mid-point between zero and the lower limit of quantification was used (7.5 IU/ml, 0.88 log IU/ml). For unquantifiable positive Xpert ® HCV Viral Load test results ("detectable below the limit of quantification of 10 IU/ml [1.0 log IU/ml]"), the mid-point between zero and the lower limit of quantification was used (5 IU/ml, 0.70 log IU/ml). 1), when HCV RNA was near the LOQ. In both cases, the capillary Xpert ® HCV VL FS result was "HCV detected <100 IU/ml". Additional Xpert ® HCV VL testing of 1 ml venous plasma confirmed the capillary measurement in the first patient (week 3, genotype 4; test result "HCV detected <10 IU/ml"), but not in the second patient.
Performance according to indication
Oroginal article
Quantitative performance
Fourteen samples (six genotype 1; one genotype 2; six genotype 3; one genotype 4) with quantifiable results in both tests were available for the correlation analysis (HCV RNA range with Cobas ® 678-3,558,156 IU/ml = 2.83-6.55 log IU/ml; HCV range with the Xpert ® HCV VL FS test 247-3,100,000 IU/ml = 2.39-6.49 log IU/ml).
Cobas ® and Xpert ® HCV VL FS test values were highly correlated (R 2 = 0.9899) ( fig. 4 ). The equation for the fitted regression line was: 
Detectable below the LOQ
There were no Cobas ® results "detectable below the LOQ" (15 IU/ml, 1.2 log IU/ml), but three capillary Xpert ® HCV VL FS tests were "detectable below the LOQ" (100 IU/ml, 2.0 log IU/ml). Two of them were undetectable with the Cobas ® assay, and for one patient (DAA treatment week 2, genotype 2), the Cobas ® result was 61 U/ml (1.79 log U/ ml). With 38 IU/ml [20] and 68 IU/ml, the highest HCV RNA values not detected by the capillary Xpert ® test were lower than the 150-250 IU/ml described as the detection threshold for the DBS method [16] . Given the at least tenfold smaller volume used compared with analyses in venous plasma or serum, decreased sensitivity of capillary methods is not surprising. However, considering that most untreated patients have HCV viral loads >1000 IU/ml [24] , capillary blood analysis is an easily applicable and reliable screening method for active hepatitis C.
Performance according to indication
Cell-associated HCV RNA in B lymphocytes present in whole blood but not in plasma might explain detectable viraemia in the capillary Xpert ® test or DBS analysis, but not in parallel plasma measurements [15, 25] . Consistent with this hypothesis, Stapleton et al. found that whole bloodbased HCV RNA detection was more sensitive than plasma-based methods [15, 26] . In our study, false positive results only occurred 2-4 and 12 weeks after DAA initiation. Longer persistence of cell-associated HCV RNA long after spontaneous clearance or successful treatment has been re-ported earlier [15, 27] . In any case, additional Xpert ® HCV VL testing of 1 ml venous plasma (LOD 4 IU/ml) confirmed that our five false positive capillary Xpert ® HCV VL tests were actually positive due to a higher sensitivity than the reference test. However, these discrepancies are probably not clinically relevant, because detectable virus under DAA treatment (including at EOT) does not predict subsequent treatment failure and/or relapse [12, 28] . Among 565 participants in an Australian cohort study of people who inject drugs, 65% preferred finger-stick over venepuncture, with 61% of these preferring to receive results in 60 min. The most common reasons for preferring finger-stick testing were rapid result (62%) and venous access difficulties (21%) [29] . Feasibility of the Xpert ® HCV VL FS assay was also demonstrated in 202 homeless people in Sydney, Australia [30] .
Another recently published study with 170 participants showed that the Xpert ® HCV VL test is able to accurately detect and quantify HCV RNA regardless of the HCV genotype in 50 µl venous whole blood collected in an EDTA tube and spotted onto a filter paper card (DBS technique) [31] . Sensitivity was 100% (119/119, 95% CI 96.9-100%) and specificity 90% (45/50, 95% CI 78.6-95.6%). On average, HCV RNA levels in whole blood were 1.93 ± 0.38 log IU/ml lower than in serum, which can be explained by the lower volume used (50 µl whole-blood eluted from DBS versus 500-1000 µl serum). There were no false negative, but five false positive results (all with HCV RNA below the LOQ of <10 IU/ml), supporting the hypothesis that whole blood-based HCV RNA detection is more sensitive than plasma-/serum-based methods.
Initially, we were concerned about an 8% error rate of the Xpert ® HCV VL FS test in the study of Lamoury et al. [12, 21] . However, all errors we observed were "insufficient volume errors" occurring after 3.5 minutes. Thus, we asked the patients to wait until this critical time-point was passed and repeated the test if necessary, which was always successful. Since the Minivette POCT 100 µl EDTA tube must be completely filled, a lancet should be used that provides enough blood volume. In the case of slow blood flow, it is advisable to repeat the capillary blood draw. The time from finger-stick to test start should be minimised to further reduce the risk of clotting of the blood sample.
Further concerns regarding the use as POCT are the availability of the GeneXpert ® -platform on site and its costs. Small GeneXpert ® platforms with one, two or four modules can be transported in a passenger car. Thus, expensive but mobile equipment can be shared by several institutions.
Our study has several strengths. Rather than being excluded, patients under DAA treatment were deliberately monitored longitudinally throughout their HCV treatment up to the SVR check. With the Xpert ® HCV VL test, a high proportion of patients (39%) was HIV co-infected. Correlation between quantifiable Xpert ® HCV VL and Cobas ® results was analysed stratified by HCV genotype, HIV status and sex, and took into account individual haematocrit values defining the plasma volume. Finally, the practicability of the capillary blood test in clinical routine is underlined by the fact that all the nurses working in our Infectious Diseases Outpatient Clinic successfully ran the tests without any support by a trained laboratory technician.
In view of the high correlation between Cobas ® in venous plasma and Xpert ® in capillary whole-blood, we additionally performed a parallel Xpert ® HCV VL test with venous plasma only for the eight plus two discordant and the two discrepant quantifiable results.
As for any single-centre study with a rather small sample size, further confirmation by an independent study is desirable, especially for the evaluation of the Xpert ® HCV VL FS test.
Conclusion
Point-of-care quantitative HCV RNA measurement in finger-stick capillary whole blood is a convenient, rapid and reliable method to diagnose active HCV infection, monitor treatment response and detect reinfection. Discordant results were rare and probably not clinically relevant, as they only occurred when HCV RNA was near the LOQ. For patients with difficult venous access after long-term intravenous drug use, capillary HCV RNA measurement removes a crucial barrier to HCV treatment and reinfection monitoring. Same-day results might improve linkage to care and allow a test-and-treat approach. The GeneXpert ® IV system connected to a laptop is easily transportable by car, which is why we use it in peripheral drug substitution centres and addiction clinics, diminishing another barrier to treatment.
Implications for future research
Whether the commercial availability of rapid point-of-care HCV RNA quantification in capillary whole blood translates into increased HCV treatment uptake remains to be determined. Reliable, rapid POCTs using capillary whole blood for anti-HAV [32, 33] , anti-HBs, HBs-Ag and anti-HBc detection [34] [35] [36] [37] remain an unmet need to identify patients requiring vaccination.
